Ipatasertib in Patients with Tumors with <i>AKT</i> Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K
The study met its primary endpoint with an ORR of 24.1% (P < 0.001), with ipatasertib demonstrating clinically significant activity in heavily pretreated patients with various tumors harboring AKT1E17K mutations. See related commentary by Dahmer Tiecher and Schram, p. 4863.
Authors
- Lyndsay N. Harris (ORCID: https://orcid.org/0000-0002-9774-6719)
- Keith T. Flaherty (ORCID: https://orcid.org/0000-0002-3402-0478)
- Peter James O'Dwyer (ORCID: https://orcid.org/0000-0002-9302-4073)
- Anuradha Pakanati (ORCID: https://orcid.org/0009-0000-5581-7999)
- Larry Rubinstein (ORCID: https://orcid.org/0000-0002-9720-9737)
- David R. Patton (ORCID: https://orcid.org/0000-0003-3855-0166)
- Lisa M. McShane (ORCID: https://orcid.org/0000-0001-8195-3206)
- Carlos L. Arteaga (ORCID: https://orcid.org/0000-0003-0870-9586)
- Alice P. Chen (ORCID: https://orcid.org/0000-0002-1426-853X)
- Barbara A. Conley (ORCID: https://orcid.org/0000-0002-1445-1684)
- Kevin Kalinsky (ORCID: https://orcid.org/0000-0002-3113-7902)
- Carolyn K. McCourt (ORCID: https://orcid.org/0000-0003-2229-8971)
- James V. Tricoli (ORCID: https://orcid.org/0000-0003-3975-8516)
- Jeremy Force (ORCID: https://orcid.org/0000-0002-3326-2715)
- Robert J. Gray (ORCID: https://orcid.org/0000-0002-5724-4917)
- Stanley R. Hamilton (ORCID: https://orcid.org/0000-0002-8331-1052)
- Zihan Wei (ORCID: https://orcid.org/0000-0001-9234-3497)
- P. Mickey Williams (ORCID: https://orcid.org/0000-0002-3309-5988)
- Victoria Wang (ORCID: https://orcid.org/0000-0003-4079-5576)
Institutions
- National Institutes of Health (US)
- City Of Hope National Medical Center (US)
- Kaiser Permanente (US)
- Emory University (US)
- Washington University in St. Louis (US)
- Massachusetts General Hospital (US)
- Southwestern Medical Center (US)
- ECOG-ACRIN Cancer Research Group (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (UA)
- Duke Medical Center (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- Panorama Research (United States) (US)
- Duke University Health System (US)
- Center for Cancer Research (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3431
- Citations
- 3
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- ECOG-ACRIN Cancer Research Group
- NRG Oncology
- National Cancer Institute